Genetic Variant Analysis for Parkinson's Disease Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies for identifying and stratifying patients with Parkinson's disease based on genetic risk factors, limiting the development of personalized therapeutic approaches.
Innovation Solution
The method involves analyzing copy number variations (CNVs) in specific genes and regions associated with Parkinson's disease, such as those impacting lysosomal and mitochondrial function, to identify genetic variations that can guide targeted treatments, including the use of specific dietary supplements and compounds like Butcher's broom, curcumin, and antioxidants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic testing and CNV analysis are implemented to identify patients with specific genetic variations, then treatment personalization and effectiveness are improved, but diagnostic complexity and cost increase
Solution Approach 1:
The diagnostic approach is segmented into distinct components: CNV analysis for detecting copy number variations, SNP analysis for single nucleotide polymorphisms, and specific gene panel testing for genes like LYG1, LYG2, SUMF1, GNS, ARSB, GALNS, and PSAP. This segmentation allows clinicians to select appropriate testing depth based on patient presentation, reducing unnecessary complexity while maintaining diagnostic accuracy for personalized treatment selection.
Solution Approach 2:
The patent applies local quality by focusing genetic testing on specific regions and genes most relevant to Parkinson's disease pathogenesis, particularly those involved in lysosomal function and mitochondrial metabolism. Rather than comprehensive whole-genome sequencing for all patients, the approach targets specific genomic regions (CNVs) and genes based on their established or suspected role in PD, optimizing resource allocation while maintaining diagnostic reliability.
2Measurement precision
If comprehensive genetic analysis including CNVs and SNPs is performed, then patient stratification accuracy is improved, but time and resource consumption increase
Solution Approach 1:
The patent implements preliminary action by performing CNV analysis as a first-line screening tool before proceeding to more comprehensive SNP analysis or specific gene testing. CNVs are detected using methods such as microarray comparative genomic hybridization (aCGH) or quantitative PCR, which can be performed relatively quickly. Based on CNV results and clinical presentation, the diagnostic workup is then tailored to focus on specific gene panels, reducing overall diagnostic time while maintaining stratification accuracy.
Solution Approach 2:
The approach applies partial action by selectively performing genetic analyses based on clinical indications and preliminary findings. Not all patients undergo complete genomic sequencing; instead, testing is tailored to the individual patient's symptoms, family history, and initial screening results. This selective approach reduces time and resource consumption while maintaining sufficient precision for clinical decision-making in most cases.
Data Source
AI summary
This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.